Covid: India to begin vaccine trials for 7 to 11-year-olds

The company is already conducting trials for children aged 12-17

Stuti Mishra
Tuesday 28 September 2021 13:11
Comments
<p>File image: India has approved just one drugmaker - Zydus Cadila - to be used in adults and children aged 12 years and above </p>

File image: India has approved just one drugmaker - Zydus Cadila - to be used in adults and children aged 12 years and above

Leer en Español

India granted approval to its largest vaccine manufacturer to conduct Covid-19 trials on children aged between seven and 11 years, as the country posted the lowest daily increase in cases in over six months.

India’s drug regulator announced that Tuesday that it has allowed vaccine maker Serum Institute (SII) to enrol kids between seven to eleven years of age for its trial of US drugmaker Novavax’s Covid-19 vaccine.

“After detailed deliberation, the committee recommended for allowing enrolment of subjects of 7 to 11 years of age group as per the protocol,” a subject expert panel of the Central Drugs Standard Control Organisation told media outlets in a briefing.

Novavax has not received authorisation in India yet, however, SII is already conducting trials on children aged 12-17 age group and has presented safety data for an initial 100 participants. So far, only drugmaker Zydus Cadila’s DNA Covid-19 vaccine has received emergency use approval in India to be used in adults and children aged 12 years and above.

However, the company’s CEO Adar Poonawalla recently said he hopes the vaccine will be approved for adults by October and for children below 18 in early 2022.

SII, considered the world’s largest vaccine maker, is also producing Covishield for India, a locally manufactured version of the Oxford-AstraZeneca vaccine. The company’s domestically produced version of Novavax will be labelled Covovax.

India’s Covid situation has been improving in recent weeks, with the country posting an increase of just 18,000 cases on Monday — the lowest since 10 March. The gradual decline has also pushed its total number of active cases below 300,000 for the first time in six months.

However, there’s a looming fear of a prospective third wave as the country tries to immunise its unjabbed population. India has so far administered 870 million doses immunising over 16 per cent of its massive 1.4 billion population with 46 per cent with one dose.

Additional reporting by agencies

Register for free to continue reading

Registration is a free and easy way to support our truly independent journalism

By registering, you will also enjoy limited access to Premium articles, exclusive newsletters, commenting, and virtual events with our leading journalists

Please enter a valid email
Please enter a valid email
Must be at least 6 characters, include an upper and lower case character and a number
Must be at least 6 characters, include an upper and lower case character and a number
Must be at least 6 characters, include an upper and lower case character and a number
Please enter your first name
Special characters aren’t allowed
Please enter a name between 1 and 40 characters
Please enter your last name
Special characters aren’t allowed
Please enter a name between 1 and 40 characters
You must be over 18 years old to register
You must be over 18 years old to register
Opt-out-policy
You can opt-out at any time by signing in to your account to manage your preferences. Each email has a link to unsubscribe.

Already have an account? sign in

By clicking ‘Register’ you confirm that your data has been entered correctly and you have read and agree to our Terms of use, Cookie policy and Privacy notice.

This site is protected by reCAPTCHA and the Google Privacy policy and Terms of service apply.

Join our new commenting forum

Join thought-provoking conversations, follow other Independent readers and see their replies

Comments

Thank you for registering

Please refresh the page or navigate to another page on the site to be automatically logged in